Adamas Pharmaceuticals, Inc.

Adamas Pharmaceuticals, Inc.

Adamas Pharmaceuticals, Inc.

Overview
Date Founded

2000

Headquarters

2200 Powell Street,Suite 220,Emeryville, CA 94608

Type of Company

Public

Employees (Worldwide)

159

Industries

Pharmaceuticals
Hospitals & Patient Services

Company Description

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

Contact Data
Trying to get in touch with decision makers at Adamas Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Founder

Chief Executive Officer

Chief Financial Officer

Secretary & General Counsel

Chief Commercial Officer

Head of Corporate Communications & Engagement

Vice President, Regulatory

Vice President, Clinical Research

Head-Human Resources

Head of Patient Access

Board of Directors

Former Co-President & Co-Chief Executive Officer at McKesson Corporation

Executive Vice President, Chief Financial Officer & Chief Business Officer at Portola Pharmaceuticals, Inc.

Chief Executive Officer at Adamas Pharmaceuticals, Inc.

Professional at Chimerix, Inc.

Chief Executive Officer & Executive Director at The Jed Foundation

Former Chief Executive Officer at Paratek Pharmaceuticals Inc.

Clinical Professor of Medicine at UCSF School of Medicine

Managing Partner at Mohr Davidow Ventures

Paths to Adamas Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Adamas Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

Stonepine Capital Management focuses primarily, but not exclusively, on equity and equity-related securities in US publicly healthcare companies. The firm seeks to invest in companies whose valuations reflect a material discount to their fundamental value in the healthcare space. Stonepine typically prefers to invest in companies at a price reflecting a discount to current commercial and financial assets alone.The Stonepine Funds' investment objective is to achieve superior absolute returns while preserving capital. They have formed Special Purpose Vehicles (SPVs) whose investment objective may differ because these investments tend to be more concentrated than the Stonepine Funds. Stonepine seeks to achieve their investment objective primarily by investing assets in publicly traded healthcare companies. Stonepine's investment focus is companies with commercial stage products generating sustainable revenue and companies with substantial financial assets (such as cash and royalty income streams).

Details Hidden

Armistice Capital is a global, long/short, value-oriented and event-driven hedge fund firm which focuses primarily on the health care and consumer sectors. They invest predominantly in equities and can be opportunistic across the capital structure. The firm seeks to maximize the opportunity set of investment candidates allowing for the selection of unique, concentrated bets to generate uncorrelated returns. They maintain significant position and portfolio level hedges in an effort to mitigate basis and market risks. Armistice Capital employs a bottom-up analysis, assessing all components of the company's capital structure and aims to take larger positions where the greatest potential risk adjusted return exists. Armistice Capital's Domestic Fund and the Offshore Fund, through their investments in the Master Fund, seek to achieve long-term capital appreciation by employing an opportunistic global long/short strategy for investing in distressed debt, value equities and event equities. In all of its investing activities, the Funds will seek to emphasize capital preservation and will seek to mitigate risk through various hedging strategies at both the position and portfolio levels.

Details Hidden

BOS engages in a disciplined, long-term investment approach and does not engage in short-term market timing in an effort to increase portfolio returns. The firm's overarching goal is to develop investment strategies that provide clients with the highest probability of achieving their financial goals. Their investment approach starts with careful consideration of each client's financial goals, constraints, and risk tolerance. The firm then develops tailored investment strategies with the goals of generating competitive long-term returns and moderating risk. They prefer low-cost investment vehicles and emphasize an investment selection process that avoids conflicts-of-interest. The methods BOS uses to analyze investments rely heavily on analytical tools and historical databases of securities prices that they have developed in-house.

Recent Transactions
Details Hidden

Adamas Pharmaceuticals, Inc. issued USD Common Stock

Details Hidden

Adamas Pharmaceuticals, Inc. issued Common Stock

Details Hidden

Adamas Pharmaceuticals, Inc. issued Common Stock

Insider Transactions
Details Hidden
Transaction Advisors
Auditor

Advised onAdamas Pharmaceuticals, Inc. issued USD Common Stock

Escrow Agent

Advised onAdamas Pharmaceuticals, Inc. issued USD Common Stock

Underwriter

Advised onAdamas Pharmaceuticals, Inc. issued Common Stock

Legal Advisor

Advised onAdamas Pharmaceuticals, Inc. issued USD Common Stock

Legal Advisor

Advised onAdamas Pharmaceuticals, Inc. issued USD Common Stock

Managing Director

Advised onAdamas Pharmaceuticals, Inc. issued USD Common Stock

Advisors & Consultants
Consultant

Former Chief Financial Officer & Vice President-Finance at Cerus Corp.

Consultant

Founder at Adamas Pharmaceuticals, Inc.

Scientific Advisor

Clinical Professor of Medicine at UCSF School of Medicine

Clients

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1984 and is headquartered in Dublin, Ireland.

Key Stats and Financials As of 2018
Market Capitalization
$156M
Total Enterprise Value
$138M
Earnings Per Share
$-4.87
Revenue
$34M
EBITDAMargin
-333.56%
EBITDA
$-114M
Total Equity
$89.9M
Net Profit
$-131M
Total Debt
$119M
Enterprise Value Sales
4.06x
Debt TEV
0.86x
TEVNet Income
-1.06x
Three Year Compounded Annual Growth Rate Of Revenue
160.95%
Five Year Compounded Annual Growth Rate Of Revenue
-13.69%
Non-Profit Donations & Grants
$5,000 - $10K
2010
Investors
Details Hidden

The Ontario Teachers Pension Plan Board's (OTPP) investments are well-diversified across a mix of public and private Canadian and non-Canadian equities, inflation-sensitive investments, fixed-income securities and real assets (real estate and infrastructure). Risk is managed carefully to reflect the plan's maturity and to decrease risk tolerance, with emphasis on outperforming the markets in which they invest. OTPP's public equity investments include stock market indices, actively managed portfolios, relationship investing and long-term equities. They use indexed equity portfolios to maintain their asset-mix policy weighting. They also manage quant portfolios that invest in global stocks based on enhanced models that seek to identify strategies and stocks with the potential to outperform relevant indices. For equity index funds, OTPP invests entirely in equity-based derivatives. OTPP's actively managed equity investments include both internally and externally managed portfolios. The firm's internally managed active equity investments are selected using bottom-up analysis to identify and invest in undervalued stocks. The majority of their investments in public companies are managed internally. OTPP's fixed-income investments include core portfolios of Canadian bonds, Ontario debentures, provincial bonds, real-return bonds and inflation-linked bonds. OTPP gains exposure to energy, metals and agricultural products through a well-known commodities index. They invest in commodities as a hedge against the cost of paying inflation-protected pensions. OTPP invests mainly through swap agreements linked to the S&P GSCI Total Return Index. The index is heavily-weighted towards oil and gas. OTPP also invests in real assets such as real estate, infrastructure and timberland to generate returns that are linked to changes in inflation and act as a hedge against the cost of paying pensions.

Details Hidden

aeris CAPITAL AG, part of SGR Sagittarius Holding AG, is a company headquartered in Pfäffikon, Switzerland, that provides investment advice.

Details Hidden

Northgate Capital focuses on global venture capital and private equity investments. The firm invests in funds operating in both developed markets and emerging markets and also makes direct investments in partnership with their venture capital and buyout funds.Northgate Capital invests in funds in developed markets including North American, European and Japanese-based private equity funds and North American and European-based venture capital funds. Within the emerging markets, Northgate Capital invests in funds in Asia, emerging European countries and Latin America, including funds operating in Brazil, Russia, India and China, as well as overlooked smaller regions. The developed market funds in which the firm invests include a mix of small-, mid- and large-cap funds. All funds are actively managed, pursue value-creation strategies and invest in companies operating in a range of industrial and regulatory environments.Northgate Capital also invests directly in promising venture capital companies across several industries and in companies with stable, yet under-realized revenue potential. The firm invests in companies that are transforming core industry sectors, ranging from energy and green technology to life sciences and information technology. Their direct investment approach begins with a screening to analyze the broad venture capital and private equity universes for high performing funds with a strong track record. They then seek to identify portfolio companies with the greatest potential including those that have overcome core technology, product development or regulatory obstacles that might have presented significant risks or barriers to market success.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Mylan NV Pharmaceuticals - Hatfield, HD

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Acorda Therapeutics, Inc. Pharmaceuticals - ARDSLEY, NY

Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its two main products are Ampyra and Zanaflex Capsules. The Ampyra is an oral drug, which treats to improve walking in patients with multiple sclerosis and Zanaflex Capsules, which is a short acting drug for the management of spasticity, a symptom of many central nervous system disorders, including multiple sclerosis and spinal cord injury. The company was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Adamas Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Adamas Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Adamas Pharmaceuticals, Inc..